openPR Logo
Press release

Hyperphosphatemia Treatment Global Market Report 2024 To 2033 | Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc

11-25-2024 01:31 PM CET | Health & Medicine

Press release from: The Business research company

Hyperphosphatemia Treatment Market Share

Hyperphosphatemia Treatment Market Share

The Business Research Company recently released a comprehensive report on the Global Hyperphosphatemia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=5852&type=smp

According to The Business Research Company's, The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4.1 billion in 2023 to $4.61 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increased incidence of chronic kidney disease (ckd), growth in aging population, high prevalence of diabetes and hypertension, expansion of dialysis patient population, advances in medical research and diagnosis of hyperphosphatemia.

The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $7.54 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with high disease burden, higher prescription share of calcium-based phosphate binders in emerging countries. Major trends in the forecast period include advancements in hyperphosphatemia treatment technologies, integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, focus on patient education and lifestyle management in hyperphosphatemia, development of novel phosphate binders and therapies.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-market-report

Market Drivers and Trends:

The increase chronic diseases among patients is driving the growth of the hyperphosphatemia treatment market. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorized as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. Furthermore, in February 2023, according to SingleCare Services LLC, a US-based healthcare savings platform, the prevalence of kidney diseases is increasing and each year untreated kidney failure claims the lives of approximately 1 million individuals. There has been an increase in hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to an increase in demand for hyperphosphatemia treatment or drugs .

Product innovations have emerged as the key trend gaining popularity in the 5G chipset market. The major players in the market are developing innovative products for market growth. For instance, in June 2021, Samsung Electronics, a South Korea-based electronics company, developed 3GPP Rel.16 compliant chipsets, a range of next-generation 5G chipsets that deliver cutting-edge 5G technologies. The new chipsets consist of a second-generation 5G modem System-on-Chip (SoC), a third-generation mmWave Radio Frequency Integrated Circuit (RFIC) chip, and a Digital Front End (DFE)-RFIC integrated chip. These are designed to increase power efficiency, boost performance, and reduce the size of 5G solutions.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Keryx Biopharmaceuticals Inc., Lupin Limited, Shire plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Abbott Laboratories, Amgen Inc., AstraZeneca plc, B. Braun Melsungen AG, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Encompass Health Corporation, FMC Corporation, Hospital Corporation of America Healthcare Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, Medtronic plc, OPKO Health Inc., Roche Diagnostics Corporation, Siemens Healthineers AG, Sysmex Corporation, Tenet Healthcare Corporation, Thermo Fisher Scientific Inc., UnitedHealth Group Inc.

Hyperphosphatemia Treatment Market 2024 Key Insights:

• The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $7.54 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%.
• Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Disease Prevalence
• Rising Emphasis On Research And Development In Hyperphosphatemia Treatment Market
• North America was the largest region in the hyperphosphatemia treatment market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=5852&type=smp

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperphosphatemia Treatment Global Market Report 2024 To 2033 | Sanofi SA, Akebia Therapeutics Inc., AMAG Pharmaceuticals Inc., Ardelyx Inc., Astellas Pharma Inc here

News-ID: 3754609 • Views:

More Releases from The Business research company

Pesticide And Other Agricultural Chemicals Industry Set to Achieve $156.05 Billion Milestone by 2029 | Steady 8.4% CAGR
Pesticide And Other Agricultural Chemicals Industry Set to Achieve $156.05 Billi …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments. What Is the Long-Term Growth Forecast for the Pesticide And Other Agricultural Chemicals Market Size 2025? In recent years, the market size for pesticides and other agricultural chemicals has witnessed significant growth. From a value of $104.46 billion in 2024, it's projected to swell to $113.13 billion in 2025, reflecting a compound
Organophosphates Pesticides Industry Expected to Reach $10.67 Billion by 2029 at 6.1% CAGR
Organophosphates Pesticides Industry Expected to Reach $10.67 Billion by 2029 at …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports. Organophosphates Pesticides Market Value Projection: How Much Will the Market Size by 2025? The market size of organophosphates pesticides has experienced consistent growth in the prior years. The market is projected to expand from $8.05 billion in 2024 to $8.41 billion in 2025, with a compound annual growth rate (CAGR) of
Nitrobenzene Industry Growth Outlook: 7.5% CAGR and $15.35 Billion by 2029
Nitrobenzene Industry Growth Outlook: 7.5% CAGR and $15.35 Billion by 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments. What Is the Long-Term Growth Forecast for the Nitrobenzene Market Size 2025? In the past few years, the size of the nitrobenzene market has witnessed significant growth. It is projected to increase from $10.96 billion in 2024 to $11.51 billion in 2025, with a compound annual growth rate (CAGR) of 5.1%. The
Nail Polish Market Analysis: $24.61 Billion by 2029 With a CAGR of 11.5%
Nail Polish Market Analysis: $24.61 Billion by 2029 With a CAGR of 11.5%
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports. Nail Polish Market Value Projection: How Much Will the Market Size by 2025? The industry of nail polish has witnessed significant expansion in the past few years. Projected to surge from $14.39 billion in 2024 to $15.93 billion in 2025, it is expected to observe a compound annual growth rate (CAGR)

All 5 Releases


More Releases for Hyperphosphatemia

Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Dis …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. What Will the Hyperphosphatemia Treatment Industry Market Size Be by 2025? The market for hyperphosphatemia treatment has expanded quickly in recent years. Its size is set to increase from $4.56 billion in 2024 to $5.13 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The extension during the historical period is
Key Influencer in the Hyperphosphatemia Treatment Market 2025: Sustainable Growt …
What industry-specific factors are fueling the growth of the hyperphosphatemia treatment market? The rise in chronic illnesses among patients is boosting the hyperphosphatemia treatment market. Conditions like cardiovascular and kidney diseases, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer all fall under the category of chronic diseases, which are non-communicable and demand long-term management. For instance, the World Health Organization reported in September 2023 that 74% of the 41 million global deaths
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising
Hyperphosphatemia Drugs Market to Witness Robust Expansion by 2029
The Hyperphosphatemia Drugs Market size is expected to grow at an annual average of CAGR 2% during the forecast period (2023-2029). Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic uncontrolled diabetes, and low
Hyperphosphatemia- Market Insight, Epidemiology and Market Forecast -2030
Hyperphosphatemia Market research report is the new statistical data source added by Infinity Business Insights. Hyperphosphatemia is a condition in which your blood contains a lot of phosphate (or phosphorus). Phosphate is an electrolyte, a chemically charged compound containing the mineral phosphorus. Phosphate is required by your body to strengthen your bones and teeth, create energy, and construct cell membranes. Phosphate, on the other hand, in excess can cause bone
Hyperphosphatemia Drugs Market Opportunity Analysis, 2018 - 2026
Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for